Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Efavirenz: enhancing the gold standard.

J R Arribas1

  • 1Internal Medicine Service, Hospital La Paz, Madrid, Spain. josearribas@telefonica.es

International Journal of STD & AIDS
|November 18, 2003
PubMed
Summary

Efavirenz remains a vital antiretroviral therapy for diverse patient groups. Its single-tablet formulation simplifies treatment, potentially improving adherence and outcomes, despite manageable side effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide in Black and Hispanic/Latine adults with HIV-1 initiating first-line therapy: 5-year follow-up from two phase III studies.

HIV medicine·2025
Same author

Three-year efficacy of switching to dolutegravir plus lamivudine: A real-world study.

HIV medicine·2023
Same author

Assessment of Noninvasive Markers of Steatosis and Liver Fibrosis in Human Immunodeficiency Virus-Monoinfected Patients on Stable Antiretroviral Regimens.

Open forum infectious diseases·2022
Same author

Clinical characteristics and outcome of hospitalized elderly patients with COVID- 19 after vaccine failure.

Vaccine·2022
Same author

Past and future of HIV infection. A document based on expert opinion.

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia·2022
Same author

Phase I dose-escalation single centre clinical trial to evaluate the safety of infusion of memory T cells as adoptive therapy in COVID-19 (RELEASE).

EClinicalMedicine·2021

Area of Science:

  • Antiviral Research
  • Pharmacology
  • Infectious Diseases

Background:

  • Efavirenz, a non-nucleoside reverse transcriptase inhibitor, has been a key antiretroviral agent since 1996.
  • It is effective in treatment-naïve, treatment-experienced, and difficult-to-treat patient populations.
  • Numerous clinical and cohort studies confirm its efficacy.

Purpose of the Study:

  • To highlight the continued importance and established efficacy of efavirenz.
  • To emphasize the benefits of its single-tablet formulation.
  • To review its tolerability profile.

Main Methods:

  • Review of clinical and cohort studies evaluating efavirenz efficacy.
  • Analysis of efavirenz's role in various patient groups.
  • Assessment of tolerability and side effect profiles.

Main Results:

  • Efavirenz demonstrates established efficacy across treatment-naïve, experienced, and difficult-to-treat patients.
  • The single 600 mg tablet formulation simplifies therapy and reduces pill burden.
  • Improved adherence and treatment outcomes are potential benefits of simplified therapy.
  • Efavirenz exhibits a well-characterized tolerability profile with mainly short-term, non-life-threatening side effects.

Conclusions:

  • Efavirenz remains a cornerstone of antiretroviral therapy due to its proven efficacy.
  • The single-tablet regimen enhances treatment adherence and outcomes.
  • Its manageable side effect profile supports its continued use.

Related Experiment Videos